Triodos Investment Management BV Increases Position in Hologic, Inc. $HOLX

Triodos Investment Management BV boosted its holdings in Hologic, Inc. (NASDAQ:HOLX) by 16.2% during the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 61,000 shares of the medical equipment provider’s stock after purchasing an additional 8,500 shares during the quarter. Triodos Investment Management BV’s holdings in Hologic were worth $3,974,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Vontobel Holding Ltd. grew its holdings in Hologic by 0.8% in the second quarter. Vontobel Holding Ltd. now owns 39,793 shares of the medical equipment provider’s stock worth $2,593,000 after purchasing an additional 318 shares during the period. Chung Wu Investment Group LLC purchased a new stake in shares of Hologic during the second quarter valued at approximately $26,000. Grimes & Company Inc. purchased a new stake in shares of Hologic during the second quarter valued at approximately $207,000. 111 Capital grew its holdings in shares of Hologic by 129.1% during the second quarter. 111 Capital now owns 16,085 shares of the medical equipment provider’s stock valued at $1,048,000 after buying an additional 9,064 shares during the last quarter. Finally, Cromwell Holdings LLC grew its holdings in shares of Hologic by 307.0% during the second quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider’s stock valued at $38,000 after buying an additional 436 shares during the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Stock Up 0.4%

Shares of Hologic stock opened at $68.62 on Friday. The company has a market cap of $15.26 billion, a price-to-earnings ratio of 28.47, a price-to-earnings-growth ratio of 2.34 and a beta of 0.63. The company’s 50 day moving average is $67.14 and its 200 day moving average is $63.26. Hologic, Inc. has a twelve month low of $51.90 and a twelve month high of $84.39. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, topping the consensus estimate of $1.05 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same period last year, the firm earned $1.06 earnings per share. The company’s quarterly revenue was up 1.2% on a year-over-year basis. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Research analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

Insiders Place Their Bets

In other Hologic news, CEO Stephen P. Macmillan sold 138,358 shares of the stock in a transaction that occurred on Monday, September 22nd. The shares were sold at an average price of $66.97, for a total value of $9,265,835.26. Following the transaction, the chief executive officer directly owned 1,234,624 shares in the company, valued at approximately $82,682,769.28. This trade represents a 10.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.88% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on HOLX. Morgan Stanley increased their price target on shares of Hologic from $65.00 to $69.00 and gave the company an “equal weight” rating in a report on Thursday, July 31st. Citigroup upgraded shares of Hologic from a “neutral” rating to a “buy” rating and increased their price target for the company from $60.00 to $80.00 in a report on Wednesday, July 9th. Wall Street Zen cut shares of Hologic from a “buy” rating to a “hold” rating in a report on Wednesday, October 1st. Argus increased their price target on shares of Hologic from $80.00 to $90.00 and gave the company a “buy” rating in a report on Friday, September 19th. Finally, Royal Bank Of Canada upgraded shares of Hologic from a “sector perform” rating to an “outperform” rating and increased their price target for the company from $72.00 to $87.00 in a report on Wednesday, August 6th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $80.15.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.